Reading:
Textbook Reading: Voet & Voet, Biochemistry, 3rd Edition, p. 959-969.
Some recent articles
(optional reading):
R. M. Garavito & A. M. Mulichak (2003) "The structure of mammalian
cyclooxygenases," Annu. Rev. Biophys. Biomol. Struct. 32: 183-206.
R. J. Soberman & P. Christmas (2003) "The organization and consequences of
eicosanoid signaling," J. Clin. Invest. 111: 1107-1113.
J. M. Schwab, H. J. Schluesener, R. Meyermann & C. N. Serhan (2003) "COX-3 the
enzyme and the concept: steps towards highly specialized pathways and precision
therapeutics?" Prostaglandins, Leukotrienes & Essential Fatty Acids 69: 339-343.
C. Brink, S.-E. Dahlen, J. Drazen, J. F. Evans, D. W. P. Hay, S. Nicosia, C. N.
Serhan, T. Shimizu & T. Yokomizo (2003) "International Union of Pharmacology
XXXVII. Nomenclature for leukotriene and lipoxin receptors," Pharmacol. Rev. 55:
195-227.
M. Romano & J. Claria (2003) "Cyclooxygenase-2 and 5-lipoxygenase converging
functions on cell proliferation and tumor angiogenesis: implications for cancer
therapy," FASEB J. 17: 1986-1995.
A. A. Spector, X. Fang, G. D. Snyder & N. L. Weintraub (2004)
"Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function," Progr.
in Lipid Res. 43: 55-90.
C. L. Bos, D. J. Richel, T. Ritsema, M. P. Peppelenbosch & H. H. Versteeg (2004)
"Prostanoids and prostanoid receptors in signal transduction," Internat. J.
Biochem. & Cell Biol. 36: 1187-1205.
A. N. Hata & R. M. Breyer (2004) "Pharmacology and signaling of prostaglandin
receptors: Multiple roles in inflammation and immune modulation," Pharm. &
Therapeutics 103: 147-166.
N. Ueno, Y. Takegoshi, D. Kamei, I. Kudo & M. Murakami (2005) "Coupling between
cyclooxygenases and terminal prostanoid synthases," Biochem. Biophys. Res. Comm.
338: 70-76.
H. Kuhn, J. Saam, S. Eibach, H.-G. Holzhutter, I. Ivanov & M. Walther (2005)
"Structural biology of mammalian lipoxygenases: Enzymatic consequences of
targeted alterations of the protein structure," Biochem. Biophys. Res. Comm.
338: 93-101.
T. Okuno, T. Yokomizo, T. Hori, M. Miyano & T. Shimizu (2005) "Leukotriene B4
receptor and the function of its helix 8," J. Biol. Chem. 280:
32049-32052.
S. Yedgar, Y. Cohen & D. Shoseyov (2006) "Control of phospholipase A2
activities for the treatment of inflammatory conditions," Biochim. Biophys. Acta
1761: 1373-1382.
M. Luo, N. Flamand & T. G. Brock (2006) "Metabolism of arachidonic acid to
eicosanoids within the nucleus," Biochim. Biophys. Acta 1761: 618-625.
O. Rådmark & B. Samuelsson (2007)
"5-Lipoxygenase: Regulation and possible involvement in atherosclerosis,"
Prostaglandins & other Lipid Mediators 83: 162-174.
T. Klein, P. Shephard, H. Kleinert & M. Kömhoff
(2007) "Regulation of cyclooxygenase-2 expression by cyclic AMP," Biochim.
Biophys. Acta 1773: 1605-1618.
M. Medhora, A. Dhanasekaran, S. K. Gruenloh, L. K. Dunn, M. Gabrilovich, J. R.
Falck, D. R. Harder, E. R. Jacobs & P. F. Pratt (2007) "Emerging mechanisms for
growth and protection of the vasculature by cytochrome P450-derived products of
arachidonic acid and other eicosanoids," Prostaglandins & other Lipid Mediators
82: 19-29.
1a. Diagram the two reactions catalyzed by PGH2
Synthase, giving
structures of substrate and product and the name of the enzyme activity for each
reaction. Name the prosthetic group and the amino acid residue that function in
catalysis. What is the significance of the final product, PGH2?
b. Describe the mechanisms by which aspirin and
ibuprofen inhibit PGH2 Synthase.
c. Briefly describe and explain the advantages to health of taking a daily aspirin.
Why are some effects of a low-dose aspirin long-lived?
Copyright © 1998-2008 by Joyce J. Diwan. All rights reserved.
|
|